A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study - (WJOG9516L)
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Alectinib (Primary) ; Crizotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jan 2021 Results published in the European Journal of Cancer
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology